1
|
Keshava HB, Rosen JE, DeLuzio MR, Kim AW, Detterbeck FC, Boffa DJ. "What if I do nothing?" The natural history of operable cancer of the alimentary tract. Eur J Surg Oncol 2017; 43:788-795. [PMID: 28131669 DOI: 10.1016/j.ejso.2016.12.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2016] [Accepted: 12/06/2016] [Indexed: 01/06/2023] Open
Abstract
INTRODUCTION "Natural history", or anticipated survival without treatment, is critical for patients weighing risks and benefits of cancer surgery. Current estimates concerning the natural history of cancer includes patients whose poor health precludes treatment; a cohort whose fate is likely distinctly worse than those eligible for surgery ("operable"). The study objective was to evaluate survival among patients recommended for cancer surgery but went untreated, to determine the natural history of "operable" alimentary tract cancer. METHODS The NCDB was queried for untreated patients with clinical stage I-III esophageal, gastric, colon, and rectal cancer diagnosed between 2003 and 2009. Untreated patients who were recommended for surgery were considered "operable," while patients coded as surgically ineligible for health reasons were "inoperable." RESULTS 5-year survival of untreated, "operable" alimentary tract cancers varied by clinical stage: esophageal cI = 10.0%, cII = 9.8%, cIII = 4.6%; gastric cI = 9.2%, cII = 5.8%, cIII = 4.3%; colon cI = 18.4%, cII = 5.0%, cIII = 10.4; and rectal cI = 17.1%, cII = 14.0%, cIII = 19.9%. At every timepoint, stage-specific survival of "operable" patients was superior to inoperable patients (p < 0.05). Additionally, median survival among "operable" patients at least doubled "inoperable" patients for each tumor. CONCLUSION Natural history of patients with "operable" alimentary tract cancer is superior to that of "inoperable" patients. Preoperative counseling should be refined to reflect this distinction.
Collapse
Affiliation(s)
- H B Keshava
- Yale School of Medicine, Department of Thoracic Surgery, USA; Cleveland Clinic Foundation, Department General Surgery, USA
| | - J E Rosen
- Yale School of Medicine, Department of Thoracic Surgery, USA
| | - M R DeLuzio
- Yale School of Medicine, Department of General Surgery, USA
| | - A W Kim
- Yale School of Medicine, Department of Thoracic Surgery, USA
| | - F C Detterbeck
- Yale School of Medicine, Department of Thoracic Surgery, USA
| | - D J Boffa
- Yale School of Medicine, Department of Thoracic Surgery, USA.
| |
Collapse
|
2
|
Dhamija A, Dhamija A, Hancock J, McCloskey B, Kim AW, Detterbeck FC, Boffa DJ. Minimally invasive oesophagectomy more expensive than open despite shorter length of stay. Eur J Cardiothorac Surg 2013; 45:904-9. [DOI: 10.1093/ejcts/ezt482] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
|
3
|
Anagnostou VK, Botsis T, Killiam E, Zolota V, Dougenis D, Tanoue L, Detterbeck FC, Syrigos KN, Bepler G, Rimm D. Molecular classification of non-small cell lung cancer using a four protein quantitative assay. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10528] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Weycker D, Jett JR, Detterbeck FC, Miller DL, Khuu A, Kennedy TC, Boyle P, Robertson JF, Hamilton-Fairley G, Edelsberg J. Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Gainor L, Parsons AM, Parker LA, Detterbeck FC, Stinchcombe T, Hayes DN. Predictive model for mediastinal lymph node status at the time of mediastinoscopy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18004 Background: Mediastinal lymph node (N2) positivity in non-small cell lung cancer (NSCLC) patients is suspected based on imaging such as CT or PET scan, with confirmation by mediastinoscopy. However, the most accurate clinical information in predicting N2 status is controversial. Methods: We reviewed 147 candidates for NSCLC resection (2000–2005) who had clinical database information available and had undergone mediastinoscopy. Using suspected clinical predictors of mediastinal metastasis available prior to mediastinoscopy, we constructed a predictive model of N2 status. Results: The largest N2 node short-axis diameter on CT was by far the most influential factor in the model. Three other predictors for N2 node positivity were significant (p<0.05) in univariate analysis: indistinct tumor borders and mediastinal invasion on CT, and mediastinal PET scan positivity. However, all were less influential than N2 size on CT. Using logistic regression, these factors can be used to predict probability of positive N2 biopsy in an individual patient. The resulting diagnostic test had a ROC (receiver operator characteristic) area of 0.80 and optimal sensitivity-specificity pairing of 75% and 73%. 35% (51/147) of patients analyzed had at least one N2 node positive at mediastinoscopy. 39% (57/147) of patients had PET scan data available, and 82% (120/147) had CT data available. Conclusions: Of available data in early-stage NSCLC patients, mediastinal lymph node size on CT scan was more important than PET scan or other CT scan findings in predicting probability of positive mediastinoscopy. A predictive model is useful in more accurately determining need for invasive staging by mediastinoscopy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Gainor
- University of North Carolina at Chapel Hill, Chapel Hill, NC; Yale New Haven Medical Center, New Haven, CT
| | - A. M. Parsons
- University of North Carolina at Chapel Hill, Chapel Hill, NC; Yale New Haven Medical Center, New Haven, CT
| | - L. A. Parker
- University of North Carolina at Chapel Hill, Chapel Hill, NC; Yale New Haven Medical Center, New Haven, CT
| | - F. C. Detterbeck
- University of North Carolina at Chapel Hill, Chapel Hill, NC; Yale New Haven Medical Center, New Haven, CT
| | - T. Stinchcombe
- University of North Carolina at Chapel Hill, Chapel Hill, NC; Yale New Haven Medical Center, New Haven, CT
| | - D. N. Hayes
- University of North Carolina at Chapel Hill, Chapel Hill, NC; Yale New Haven Medical Center, New Haven, CT
| |
Collapse
|
6
|
Lally BE, Detterbeck FC, Thomas CR, Machtay M, Miller AA, Oaks TE, Petty WJ, Robbins ME, Blackstock AW. Risk of cardiac (CD) and pulmonary (PD) death after post-operative radiotherapy (PORT) for non-small cell lung cancer (NSCLC): Analysis of the Surveillance, Epidemiology, and End-Results (SEER) program. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6122 Background: Since radiation treatment planning and delivery techniques have evolved over time, we investigated if the risk of CD and PD after PORT for NSCLC has decreased. Methods: We selected postoperative patients with non-metastatic NSCLC diagnosed in 1980–1995 from the SEER data. To account for peri-operative mortality, patients with survival less than 6 months were excluded. Variables analyzed included age, gender, laterality, disease stage, SEER geographic region, ethnicity/race, and histology. CD and PD were calculated at 10 years and compared for patients diagnosed during 1980–83, 1984–88, 1989–91, and 1992–95. Cox proportional hazards models (CPHM) were used to calculate the hazard of CD and PD. Results: This analysis included 29,093 patients treated with observation (OB) and 8334 patients who received PORT. For the patients treated with OB, the 10 yr mortality rates for CD/PD were 17%/2%, 15%/3%, 15%/3%, and 14%/<0.1% for years of diagnosis of 1980–83, 1984–88, 1989–91, and 1992–95, respectively. For the patients who were treated with PORT, the 10 yr mortality rates for CD/PD were 21%/3%, 21%/4%, 15%/4%, and 14%/<0.1% for years of diagnosis of 1980–83, 1984–88, 1989–91, and 1992–95, respectively. CPHM showed the hazard of CD for patients treated with OB to be significantly decreasing; 1980–83 (HR=1.412; CI=1.257–1.585; p<0.0001), 1984–88 (HR=1.260; CI=1.124–1.413; p<0.0001), 1989–91 (HR=1.180; CI=1.054–1.321; p=0.0042), and 1992–95 (HR=1.00; Ref.). CPHM showed the hazard of CD for patients who received PORT to be significantly decreasing; 1980–83 (HR=1.568; CI=1.222–2.011; p=0.0004), 1984–88 (HR=1.435; CI=1.125–1.830; p=0.0036), 1989–91 (HR=0.992; CI=0.767–1.282; p=0.9504), and 1992–95 (HR=1.00; Ref.). Although PD showed a similar decreasing trend relative to year of diagnosis, CPHM did not demonstrate this to be statistically significant. Conclusions: There was a greater reduction in the CD rate in the PORT group compared to the OB group. While there appeared to be a trend in the reduction of PD, the results were not significant which may be secondary to too few events occurring. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. E. Lally
- Wake Forest University School of Medicine, Winston Salem, NC; Yale University School of Medicine, New Haven, CT; Oregon Health and Science University, Portland, OR; Thomas Jefferson University, Philadelphia, PA
| | - F. C. Detterbeck
- Wake Forest University School of Medicine, Winston Salem, NC; Yale University School of Medicine, New Haven, CT; Oregon Health and Science University, Portland, OR; Thomas Jefferson University, Philadelphia, PA
| | - C. R. Thomas
- Wake Forest University School of Medicine, Winston Salem, NC; Yale University School of Medicine, New Haven, CT; Oregon Health and Science University, Portland, OR; Thomas Jefferson University, Philadelphia, PA
| | - M. Machtay
- Wake Forest University School of Medicine, Winston Salem, NC; Yale University School of Medicine, New Haven, CT; Oregon Health and Science University, Portland, OR; Thomas Jefferson University, Philadelphia, PA
| | - A. A. Miller
- Wake Forest University School of Medicine, Winston Salem, NC; Yale University School of Medicine, New Haven, CT; Oregon Health and Science University, Portland, OR; Thomas Jefferson University, Philadelphia, PA
| | - T. E. Oaks
- Wake Forest University School of Medicine, Winston Salem, NC; Yale University School of Medicine, New Haven, CT; Oregon Health and Science University, Portland, OR; Thomas Jefferson University, Philadelphia, PA
| | - W. J. Petty
- Wake Forest University School of Medicine, Winston Salem, NC; Yale University School of Medicine, New Haven, CT; Oregon Health and Science University, Portland, OR; Thomas Jefferson University, Philadelphia, PA
| | - M. E. Robbins
- Wake Forest University School of Medicine, Winston Salem, NC; Yale University School of Medicine, New Haven, CT; Oregon Health and Science University, Portland, OR; Thomas Jefferson University, Philadelphia, PA
| | - A. W. Blackstock
- Wake Forest University School of Medicine, Winston Salem, NC; Yale University School of Medicine, New Haven, CT; Oregon Health and Science University, Portland, OR; Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
7
|
Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Obasaju CK, Bloss LP, Socinski MA. The impact of neoadjuvant chemotherapy and surgery on quality of life (QL) in patients with early stage NSCLC: A prospective analysis of the GINEST project. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. J. Gralla
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - M. J. Edelman
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - F. C. Detterbeck
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - T. M. Jahan
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - D. M. Loesch
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - S. A. Limentani
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - R. Govindan
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - C. K. Obasaju
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - L. P. Bloss
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - M. A. Socinski
- New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenbaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| |
Collapse
|
8
|
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Bloss LP, Obasaju CK. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early stage non-small cell lung cancer (NSCLC): Initial results of the GINEST • project. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. C. Detterbeck
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - M. A. Socinski
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - R. J. Gralla
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - M. J. Edelman
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - T. M. Jahan
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - D. M. Loesch
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - S. A. Limentani
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - R. Govindan
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - L. P. Bloss
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| | - C. K. Obasaju
- Univ of North Carolina, Chapel Hill, NC; New York Lung Cancer Alliance, New York, NY; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Central Indiana Cancer Centers, Indianapolis, IN; Blumenthal Cancer Ctr, Charlotte, NC; Washington Univ Oncology, St Louis, MO; Eli Lilly & Co, Indianapolis, IN
| |
Collapse
|
9
|
Rivera MP, Detterbeck FC, Socinski MA, Moore D, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Obasaju CK, Gralla RJ. Neoadjuvant chemotherapy with gemcitabine-containing regimens in stage I-II non-small cell lung cancer (NSCLC): Initial results of pre-operative pulmonary function testing (PFTs) in the GINEST project. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. P. Rivera
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| | - F. C. Detterbeck
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| | - M. A. Socinski
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| | - D. Moore
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| | - M. J. Edelman
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| | - T. M. Jahan
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| | - R. H. Ansari
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| | - J. D. Luketich
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| | - C. K. Obasaju
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| | - R. J. Gralla
- The Univ of North Carolina at Chapel Hill, Chapel Hill, NC; Univ of North Carolina, Chapel Hill, NC; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of CA San Francisco, San Francisco, CA; Michiana Hem/Oncology, South Bend, IN; Univ of Pittsburgh Physicians, Pittsburgh, PA; Eli Lilly & Co, Indianapolis, IN; New York Lung Cancer Alliance, New Yor, NY
| |
Collapse
|
10
|
Egan TM, Detterbeck FC, Mill MR, Bleiweis MS, Aris R, Paradowski L, Retsch-Bogart G, Mueller BS. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg 2002; 22:602-9. [PMID: 12297180 DOI: 10.1016/s1010-7940(02)00376-7] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
OBJECTIVES We reviewed our experience with lung transplant for cystic fibrosis (CF) over a 10-year period to identify factors influencing long-term survival. METHODS One hundred and twenty-three patients with CF have undergone 131 lung transplant procedures at our institution; 114 have had bilateral sequential lung transplants (DLTX) and nine have had bilateral lower lobe transplants from living donors. Three patients had retransplant for acute graft failure, and five had late retransplant for bronchiolitis obliterans syndrome (BOS). Kaplan-Meier survival was calculated for the entire cohort and for subsets at higher risk of death to determine factors predicting a better outcome. RESULTS Actuarial survival for the entire group of DLTX CF patients was 81% at 1 year, 59% at 5 years, and 38% at 10 years. Lobar transplant was associated with a poorer survival (37.5% at 1 and 5 years). Among DLTX patients, colonization with Burkholderia cepacia was present in 22 patients and was associated with poorer outcome (1- and 5-year survival 60 and 36% in B. cepacia patients vs. 86 and 64% in non-cepacia patients). DLTX patients younger than age 20 (n=22) had a similar survival to patients age 20 or older (n=90). Being on a ventilator at the time of transplant was not associated with poorer survival (n=8). BOS affects increasing numbers of survivors with time. Five CF patients have been retransplanted due to BOS with one operative death and 1-year survival of 60%. CONCLUSIONS DLTX has acceptable long term survival in CF adults and children with end stage disease. CF patients colonized with B. cepacia have a worse outcome but transplantation is still warranted.
Collapse
Affiliation(s)
- T M Egan
- Division of Cardiothoracic Surgery, Department of Surgery, University of North Carolina at Chapel Hill, 108 Burnett-Womack Building, UNC, Chapel Hill, NC 27599-7065, USA.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001; 92:1213-23. [PMID: 11571735 DOI: 10.1002/1097-0142(20010901)92:5<1213::aid-cncr1440>3.0.co;2-0] [Citation(s) in RCA: 144] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND A modified Phase I/II trial was conducted evaluating the incorporation of three-dimensional conformal radiation therapy into a strategy of sequential and concurrent carboplatin/paclitaxel in Stage III unresectable nonsmall cell lung carcinoma (NSCLC). The dose of thoracic conformal radiation therapy (TCRT) from 60 to 74 gray (Gy) was increased. Endpoints included response rate, toxicity, and survival. METHODS Sixty-two patients with unresectable Stage III NSCLC were included. Patients received 2 cycles of induction carboplatin (area under the concentration curve [AUC], 6) and paclitaxel (225 mg/m(2) over 3 hours) every 21 days. On Day 43, concurrent TCRT and weekly (x 6) carboplatin (AUC, 2) and paclitaxel (45 mg/m(2)/3 hours) were initiated. The TCRT dose was escalated from 60 to 74 Gy in 4 cohorts (60, 66, 70, and 74 Gy). RESULTS The response rate to induction carboplatin/paclitaxel was 40%. Eight patients (13%) progressed on the induction phase. No dose-limiting toxicity was observed during the escalation of the TCRT dose from 60 to 74 Gy. The major toxicity was esophagitis, however, only 8% developed Grade 3/4 esophagitis using Radiation Therapy Oncology Group criteria. The overall response rate was 52%. Survival rates at 1, 2, 3, and 4 years were 71%, 52%, 40%, and 36%, respectively, with a median survival of 26 months. The 1-, 2-, and 3-year progression free survival probabilities were 47%, 35%, and 29%, respectively. CONCLUSIONS Incorporation of TCRT with sequential and concurrent carboplatin/paclitaxel is feasible, and dose escalation of TCRT to 74 Gy is possible with acceptable toxicity. Overall response and survival rates are encouraging. Both locoregional and distant failure remain problematic in this population of patients.
Collapse
Affiliation(s)
- M A Socinski
- Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
BACKGROUND Tracheobronchial injury is a recognized, yet uncommon, result of blunt trauma to the thorax. Often the diagnosis and treatment are delayed, resulting in attempted surgical repair months or even years after the injury. This report is an extensive review of the literature on tracheobronchial ruptures that examines outcomes and their association with the time from injury to diagnosis. METHODS We reviewed all patients with blunt tracheobronchial injuries published in the literature to determine the anatomic location of the injury, mechanism of the injury, time until diagnosis and treatment, and outcome. Only patients with blunt intrathoracic tracheobronchial traumas were included. RESULTS We identified 265 patients reported between 1873 and 1996. Motor vehicle accidents were the most frequent mechanism of injury (59%). The overall mortality among reported patients has declined from 36% before 1950 to 9% since 1970. The injury occurred within 2 cm of the carina in 76% of patients, and 43% occurred within the first 2 cm of the right main bronchus. The proximity of the injury to the carina had no detectable effect on mortality. Injuries on the right side were treated sooner but were associated with a higher mortality than left-sided injuries. No association was detected between delay in treatment and successful repair of the injury; ninety percent of patients undergoing treatment more than 1 year after injury were repaired successfully. CONCLUSIONS This review of patients with blunt tracheobronchial injuries represents the largest cohort studied to date. These data suggest an ability to repair tracheobronchial injuries successfully many months after they occur. We are also able to assess the mortality associated with the location and side of injury, examine the time from injury until diagnosis and treatment, and evaluate treatment outcome.
Collapse
Affiliation(s)
- A C Kiser
- Department of Surgery, University of North Carolina School of Medicine, Chapel Hill 27599-7065, USA
| | | | | |
Collapse
|
13
|
Socinski MA, Rosenman JG, Schell MJ, Halle J, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. Cancer 2000; 89:534-42. [PMID: 10931452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
BACKGROUND A modified Phase I trial was conducted evaluating the incorporation of 3-dimensional conformal radiation therapy (3DCRT) into a strategy of sequential and concurrent carboplatin/paclitaxel in Stage III, unresectable nonsmall cell lung carcinoma (NSCLC). In addition, dose escalation of thoracic conformal radiation therapy (TCRT) from 60 to 74 gray (Gy) was performed. Endpoints included response rate, toxicity, and survival. METHODS Twenty-nine patients with unresectable Stage III NSCLC were included. Patients received 2 cycles of induction carboplatin (AUC 6) and paclitaxel (225 mg/m(2)/3 hours) every 21 days. On Day 43, concurrent TCRT and weekly (x6) carboplatin (AUC 2) and paclitaxel (45 mg/m(2)/3 hours) was initiated. The TCRT dose was escalated from 60 to 74 Gy in 4 cohorts. RESULTS The response rate to induction carboplatin/paclitaxel was 52%. Three patients (10%) experienced disease progression during the induction phase. No dose-limiting toxicity was seen during the escalation of the TCRT dose from 60 to 74 Gy. The major toxicity was esophagitis, with 18% of patients developing Radiation Therapy Oncology Group Grade 3 esophagitis. The overall response rate was 70% (1 complete response and 18 partial responses). Survival rates at 1 and 2 years were 69% and 45%, with a median survival of 21 months. The 1-year progression free survival probability was 41% (95% confidence interval, 23-59%). CONCLUSIONS Incorporation of 3DCRT with sequential and concurrent carboplatin/paclitaxel is feasible, and dose escalation of TCRT to 74 Gy is possible with acceptable toxicity. Overall response and survival rates are encouraging. Accrual is continuing in a Phase II fashion at 74 Gy with sequential and concurrent carboplatin/paclitaxel.
Collapse
Affiliation(s)
- M A Socinski
- Multidisciplinary Thoracic Oncology Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7305, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Schroen AT, Detterbeck FC, Crawford R, Rivera MP, Socinski MA. Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. Chest 2000; 118:129-37. [PMID: 10893370 DOI: 10.1378/chest.118.1.129] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
STUDY OBJECTIVES The physicians who initially evaluate patients with non-small cell lung cancer (NSCLC) strongly impact the course of therapy. Their beliefs in treatment and prognosis may contribute to practices of variable quality and appropriateness. We sought to better describe beliefs among pulmonologists and thoracic surgeons who were selected for guiding early therapy and referrals in patients with NSCLC. DESIGN Mail questionnaire focusing on survival estimates, treatment perceptions, and referral patterns. PARTICIPANTS Twelve hundred pulmonologists and 800 thoracic surgeons who were clinically active members of the American College of Chest Physicians. MEASUREMENTS AND RESULTS Response rates of 50% for pulmonologists and 52% for thoracic surgeons were obtained after two mailings. Five-year survival estimates for patients with resected stage I NSCLC revealed that 30% of respondents overestimated survival rates and 18% underestimated survival rates. The underestimation of survival rate was found among more respondents who are practicing pulmonology than thoracic surgery (22% vs 10% [corrected], respectively), who were trained before 1980 than after 1980 (29% vs 10% [corrected], respectively), and who were seeing < 10 lung cancer patients annually than those who were seeing > 25 (31% vs 0.14%, respectively). Beliefs in the survival benefit of adjuvant chemotherapy or of radiation in stage I-IIIA disease divided respondents within both specialties. Chemotherapy plus radiation vs radiation alone in unresectable stage IIIA-B NSCLC was viewed as benefiting survival less often by physicians seeing < 10 lung cancer patients annually rather than > 25 (57% vs 77% [corrected], respectively) and by physicians underestimating rather than correctly estimating survival in early-stage disease (58% vs 72% [corrected], respectively). Chemotherapy was believed to confer survival benefits in patients with stage IV disease by one third of respondents. CONCLUSIONS Certain physician characteristics, particularly the length of time since training and NSCLC patient volume, are associated with beliefs not conclusively supported in the medical literature or with opinions inconsistent within and between specialties.
Collapse
Affiliation(s)
- A T Schroen
- Robert Wood Johnson Clinical Scholars Program, University of North Carolina, Chapel Hill, NC, USA
| | | | | | | | | |
Collapse
|
15
|
Abstract
BACKGROUND Induction chemoradiotherapy followed by surgery may improve survival of patients with esophageal carcinoma. Computed tomography (CT) has been used to evaluate the tumor response after completing induction chemoradiotherapy. The authors examined the ability of CT to evaluate the pathologic tumor response to induction therapy and to stage the tumor correctly. METHODS Preinduction and postinduction chemoradiotherapy CT scans were reviewed retrospectively for 50 patients enrolled in a protocol of induction chemoradiotherapy followed by surgery. All studies were performed on third-generation or fourth-generation scanners. Radiographic response was determined using Eastern Cooperative Oncology Group solid tumor response criteria for bidimensional measurable disease. This was compared with the pathologic tumor response. CT-tumor (T) classification using the modified Tio scale was compared with the pathologic T classification. RESULTS CT-T classification did not correlate with the pathologic stage (P = 0.09) or the pathologic tumor response (P = 0.22). The postinduction chemoradiotherapy CT accurately staged the T classification in 42% of patients but overstaged 36% of patients and understaged 20% of patients. CT had a sensitivity of 65%, a specificity of 33%, a positive predictive value of 58%, and a negative predictive value of 41% in evaluating the pathologic tumor response. CONCLUSIONS CT is a poor diagnostic study tool for determining the pathologic tumor response or the pathologic disease stage after induction chemoradiotherapy in patients with esophageal carcinoma.
Collapse
Affiliation(s)
- D R Jones
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill 27599-7065, USA
| | | | | | | |
Collapse
|
16
|
Egan TM, Detterbeck FC, Mill MR, Gott KK, Rea JB, McSweeney J, Aris RM, Paradowski LJ. Lung transplantation for cystic fibrosis: effective and durable therapy in a high-risk group. Ann Thorac Surg 1998; 66:337-46. [PMID: 9725366 DOI: 10.1016/s0003-4975(98)00496-2] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND The purpose of this study was to review our experience with lung transplantation in patients with end-stage cystic fibrosis. METHODS Eight-two patients with cystic fibrosis have undergone bilateral lung transplantation (n=76) or bilateral lower lobe transplantation (n=6) since October 1990. RESULTS Actuarial survival for the entire cohort is 79% at 1 year and 57% at 5 years. The development of bronchiolitis obliterans syndrome is the leading cause of death after the first year. Freedom from bronchiolitis obliterans syndrome is 84% at 1 year and 51% at 3 years. Pulmonary function tests improve dramatically in recipients. There was no association between death within 1 year and recipient age, weight, graft ischemic time, cytomegalovirus seronegativity, or the presence of pan-resistant organisms. Similarly, there was no association between the development of bronchiolitis obliterans syndrome within 2 years and ischemic time, number of rejection episodes, cytomegalovirus seronegativity, or the presence of panresistant organisms. CONCLUSIONS Despite their poor nutritional status and the presence of multiply resistant organisms, patients with cystic fibrosis can undergo bilateral lung transplantation with acceptable morbidity and mortality.
Collapse
Affiliation(s)
- T M Egan
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill 27599-7065, USA
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
Pancoast or superior pulmonary sulcus tumors are uncommon primary bronchogenic carcinomas that produce a characteristic clinical syndrome of upper extremity pain and Horner's syndrome. Treatment of patients with this malignancy has traditionally involved irradiation alone or preoperative irradiation followed by resection. Recent advances in the management of Pancoast tumors include the importance of mediastinoscopy in staging the tumor before treatment begins. A complete resection should be accomplished including a lobectomy whenever possible. The current treatment protocol involves induction chemoradiotherapy followed by surgery.
Collapse
Affiliation(s)
- D R Jones
- Division of Cardiothoracic Surgery, University of North Carolina, Chapel Hill 27599-7065, USA
| | | |
Collapse
|
18
|
Abstract
BACKGROUND The use of video-assisted thoracic surgery for diagnosis and treatment of mediastinal tumors in a multiinstitution patient population is not well understood. METHODS We studied 48 cases from Cancer and Leukemia Group B thoracic surgeons. Of 21 men and 27 women, aged 41 +/- 16 years, 22 patients were asymptomatic. In the others, 92% of tumor-related symptoms improved or resolved after treatment. Five tumors involved the anterior compartment, 19 the middle, and 24 the posterior compartment. Diagnoses were typical for each compartment but also included uncommon problems such as superior vena cava hemangioma and a histoplasmosis cyst causing hoarseness. Of the lesions, a biopsy of 12 was done without excision and the rest were excised completely. Fifteen were cystic and 10 were malignant (8 biopsy only). Maximal dimensions were 5.2 +/- 3.3 cm. RESULTS Operations were briefer for 24 posterior (93 +/- 41 min) than 5 anterior (195 +/- 46 min, p < 0.01) or 19 middle mediastinal tumors (170 +/- 78 min, p < 0.01). Although 96% had vital mediastinal relations, only six open conversions were performed because of bleeding (n = 3), large size, impaired exposure, or rib attachments, and no patient had morbidity beyond that expected for the thoracotomy. Postoperative stay was shorter for the nonconversion group (3.2 +/- 2.8 versus 5.5 +/- 2.1 days, p = 0.05), as was chest tube duration (1.7 +/- 1.4 days versus 3.2 +/- 1.9 days, p = 0.03). There were no postoperative deaths or major complications, but 7 patients had minor complications. During a mean of 20 months of surveillance (range, 1 to 52 months), one cyst recurred (asymptomatic) as did one sarcoma that was excised. CONCLUSIONS Video-assisted thoracic surgery is a safe technique for benign mediastinal tumors, typically those in the middle and posterior mediastinum.
Collapse
Affiliation(s)
- T L Demmy
- Division of Cardiothoracic Surgery, University of Missouri Hospital and Clinics, Columbia, USA
| | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Carcinoid tumors have been described in almost every organ and may affect virtually every body system. Cardiac involvement manifesting as right-sided valvular disease is characteristic of the carcinoid syndrome; however, direct myocardial involvement is unusual. We present a case of an invasive carcinoid tumor whose primary manifestation was myocardial invasion.
Collapse
Affiliation(s)
- M H Hennington
- Hickory Heart, Lung, and Vascular Associates, Hickory, North Carolina, USA
| | | | | | | |
Collapse
|
20
|
Abstract
It has been suggested that T3/N0-1/M0 non-small cell lung cancer should be classified as stage IIB rather than IIIA. This is the result of a widespread perception that the survival of patients with T3/N0-1 lung cancers greatly exceeds that of patients with stage IIIA (N2) lung cancers. This perception is based primarily on the survival of T3/N0-1 patients who have chest wall involvement. However, the T3 classification also includes tumors that involve mediastinal structures, the main stem bronchus <2 cm from the carina, and the brachial plexus as seen in Pancoast tumors. Survival for each of these T3 categories is examined in this articles and found to be somewhat different. The available data show that patients with T3/N0-1 tumors involving the chest wall have a good prognosis after resection, whereas patients with central T3/N0-1 tumors (mediastinal or main stem bronchial involvement) have a prognosis similar to that of patients with resected IIIA (N2) tumors. If a new classification of T3/N0-1 tumors as stage IIB is to be adopted, it will be important for future studies to document which type of T3 tumor is being discussed.
Collapse
Affiliation(s)
- F C Detterbeck
- Multidisciplinary Thoracic Oncology Program, University of North Carolina School of Medicine, Chapel Hill, USA
| | | |
Collapse
|
21
|
Jones DR, Detterbeck FC, Egan TM, Parker LA, Bernard SA, Tepper JE. Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. Ann Thorac Surg 1997; 64:185-91; discussion 191-2. [PMID: 9236358 DOI: 10.1016/s0003-4975(97)00449-9] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Induction chemoradiotherapy followed by esophagectomy may provide results superior to those of single-modality treatment in patients with esophageal cancer. The purpose of this study was to review our experience with this approach for esophageal cancer. METHODS From 1988 to 1996, 166 consecutive patients with esophageal cancer were evaluated; 66 entered a protocol of chemotherapy (5-fluorouracil, cisplatin) concurrent with radiation (45 Gy) followed by esophagectomy. Fifty-four patients completed the protocol. RESULTS Toxicity associated with induction chemoradiotherapy was minimal. The actuarial survival at 12, 24, and 36 months was 59%, 42%, and 32%, respectively. The pathologic complete response (pCR) rate was 41%, with 12-, 24-, and 36-month survivals of 77%, 50%, and 45%, whereas non-pCR patients had survivals of 46%, 35%, and 23%. The difference in survival between pCR and non-pCR patients was not significant (p = 0.13), but the difference in recurrence-free survival was significant (p = 0.007). CONCLUSIONS This well-tolerated protocol resulted in a high pCR. Trimodality treatment for esophageal cancer may provide long-term survival in some patients regardless of their pCR status.
Collapse
Affiliation(s)
- D R Jones
- Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill 27599-7065, USA
| | | | | | | | | | | |
Collapse
|
22
|
Kelekis NL, Semelka RC, Molina PL, Warshauer DM, Sharp TJ, Detterbeck FC. Immediate postgadolinium spoiled gradient-echo MRI for evaluating the abdominal aorta in the setting of abdominal MR examination. J Magn Reson Imaging 1997; 7:652-6. [PMID: 9243383 DOI: 10.1002/jmri.1880070407] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
To assess the reproducibility and image quality of immediate postgadolinium chelate spoiled gradient-echo MRI in demonstrating disease of the abdominal aorta. All patients (27 patients: 21 men, 6 women) with substantial disease of the abdominal aorta, who underwent abdominal MR examinations at 1.5 T between 1991 and 1995, were entered in the study. Patients were referred for evaluation of suspected aortic disease (14 patients) or other abdominal diseases (13 patients). Three experienced investigators manually measured luminal and external aortic wall diameters and rated image quality, definition of inner and outer walls, extent of disease, and presence of other abdominal abnormalities, in an independent fashion. A cardiovascular surgeon then rated all studies to determine whether clinical management could be based on the MR findings alone. There was 98 to 99% agreement in measurements of luminal and external wall diameter between the three investigators. Overall image quality was rated as good in 77.8 to 88.9% of patients. A total of 31 additional nonaortic abdominal abnormalities were detected by all observers. The cardiovascular surgeon rated 25 of 27 studies as adequate to determine clinical management based on MR findings alone. Immediate postgadolinium spoiled gradient-echo MRI is a reproducible technique for the demonstration of abdominal aortic disease and possesses good image quality. Advantages of this technique include simultaneous evaluation of other nonvascular diseases of the abdomen, short examination time, and easy implementation as part of routine abdominal MRI scanning protocol.
Collapse
Affiliation(s)
- N L Kelekis
- Department of Radiology, University of North Carolina at Chapel Hill 27599-7510, USA
| | | | | | | | | | | |
Collapse
|
23
|
Abstract
Primary carcinomas arising in the apex of the lung (Pancoast tumors) have attracted attention because of the characteristic syndrome that is produced by local extension into the chest wall and the brachial plexus. This article reviews the history of the treatment of this disease, the natural history of untreated patients, and the diagnosis of Pancoast tumors. The published data on results, prognostic factors, and technical aspects of treatment with combined irradiation and operation are examined, as well as those pertaining to treatment with irradiation alone.
Collapse
Affiliation(s)
- F C Detterbeck
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill, USA
| |
Collapse
|
24
|
Socinski MA, Detterbeck FC, Rivera MP, Egan TM, Halle J, Rosenman J. Chemotherapy helps patients with advanced non-small cell carcinoma of the lung. N C Med J 1996; 57:281-6. [PMID: 8854691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- M A Socinski
- Multidisciplinary Thoracic Oncology Program, University of North Carolina Department of Medicine, Chapel Hill 27599, USA
| | | | | | | | | | | |
Collapse
|
25
|
Abstract
BACKGROUND Between June 1997 and November 1993, 100 consecutive thymectomies for myasthenia gravis were performed at University of North Carolina Hospitals in Chapel Hill. METHODS A consistent, planned protocol involving preoperative, intraoperative, and postoperative care was followed. All thymectomies were performed through a median sternotomy with removal of all visible thymus and perithymic fat in the anterior mediastinum. RESULTS There was no perioperative mortality or longterm morbidity. Mean postoperative hospital stay was 6.3 days (range, 3 to 18 days). Ninety-six percent of the patients were extubated the day of the operation, and all patients were extubated within 24 hours. Mean postoperative intensive care unit stay was 1.2 days (range, 1 to 4 days). After a mean follow-up of 65 months (range, 1 to 199 months), 78% of all patients are improved by at least one modified Osserman classification when their current status is compared with their worst preoperative disease severity. In fact, 69% of patients with mild disease preoperatively (class I, II, or III maximal severity) are in pharmacologic remission (asymptomatic without regular medication), whereas 29% of patients with severe disease (class IV or V) are in remission (p = 0.0001). CONCLUSIONS Our programmatic approach to thymectomy through a sternotomy has shown minimal morbidity and mortality. It is beneficial to myasthenics at both ends of the age and severity spectrum.
Collapse
Affiliation(s)
- F C Detterbeck
- Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, USA
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
Bone destruction as a manifestation of Wegener's granulomatosis has been reported, but these cases were limited to the head and face. We present a case in which a sternal abscess was the initial manifestation of Wegener's granulomatosis. We believe this is the first reported case of bone destruction due to Wegener's occurring in a location other than the head and face.
Collapse
Affiliation(s)
- M H Hennington
- Department of Sugery, University of North Carolina School of Medicine, Chapel Hill, USA
| | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
The transverse thoracosternotomy provides excellent exposure for repair of lesions involving the entire thoracic aorta. This approach has been made more feasible by other recent technical advances, such as retrograde perfusion of the brain during circulatory arrest, allowing single-stage replacement of the ascending and descending aorta and aortic arch. The two cases presented here illustrate the use of these advancements in the treatment of extensive aneurysms of the thoracic aorta.
Collapse
Affiliation(s)
- F C Detterbeck
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill, 27599-7065, USA
| | | |
Collapse
|
28
|
Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996; 14:156-63. [PMID: 8558191 DOI: 10.1200/jco.1996.14.1.156] [Citation(s) in RCA: 169] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
PURPOSE A prospective study was performed to determine the outcome of patients with esophageal cancer who received preoperative radiation therapy and chemotherapy followed by esophagectomy, and to determine the role of preresection esophagogastroduodenoscopy (EGD) in predicting the patients in whom surgery could possibly be omitted, and the impact of surgery on survival. MATERIALS AND METHODS Thirty-five patients with localized carcinoma of the esophagus received concurrent external-beam radiotherapy and chemotherapy followed by esophagectomy. Patients received 45 Gy in 25 fractions. Chemotherapy consisted of continuous infusion fluorouracil (5-FU; 1,000 mg/m2/d) on days 1 through 4 and 29 through 32 and cisplatin (100 mg/m2) on day 1. Patients underwent an Ivor-Lewis esophagectomy 18 to 33 days after completion of radiotherapy. RESULTS Eighty percent of the patients had squamous cell carcinoma and 20% had adenocarcinoma. In addition, 51% had a pathologic complete response (CR). Twenty-two of the 35 underwent a preresection EGD before resection. Seventeen of the 22 (77%) had negative pathology from the preresection EGD, but seven of the 17 (41%) had residual tumor at surgery. The median survival and disease-free survival rates for all patients were 25.8 months and 32.8 months, respectively. Eighteen patients (51%) had no tumor at resection. The median survival for these patients was 36.8 months; the median disease-free survival time has not been reached. The median survival and disease-free survival rate for the patients with residual tumor in the surgical specimen were 12.9 months and 10.8 months, respectively. CONCLUSION Preresection EGD is not reliable for determining the presence of residual disease or the patients in whom surgery could be omitted. Twenty-five percent of the patients with residual tumor in the resected surgical specimen were long-term survivors; this suggests a benefit from esophagectomy after concurrent radiotherapy and chemotherapy.
Collapse
Affiliation(s)
- B A Bates
- Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill 27599-7512, USA
| | | | | | | | | |
Collapse
|
29
|
Detterbeck FC, Egan TM, Mill MR. Lung transplantation after previous thoracic surgical procedures. Ann Thorac Surg 1995; 60:139-43. [PMID: 7598576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND This study examined results of lung transplantation after previous thoracic surgical procedures. METHODS Twenty percent of the 69 isolated lung transplantations performed at the University of North Carolina between January 1990 and June 1993 were in patients who had undergone a previous thoracic surgical procedure, and an additional 10% had undergone a previous chest tube placement. RESULTS No statistically significant increase in morbidity or mortality was observed between those having undergone a previous procedure or chest tube placement and all other patients. Specifically, the length of intubation, length of hospital stay, hospital mortality, or the number of patients who experienced major early complications was not significantly different between these groups. A statistically significant increase in the number of blood products used was observed in the patients with previous thoracic surgical procedures but not with patient having had previous chest tube placements. However, when the data were reanalyzed with respect to the use of cardiopulmonary bypass, those patients requiring bypass had a markedly poorer outcome that reached statistical significance in all of the parameters studied: hospital death, incidence of major complications, length of intubation, hospital stay, incidence of bleeding, and number of blood products used. CONCLUSIONS We conclude that although increased bleeding may be encountered, lung transplantation can be performed successfully in patients who have had previous thoracic surgical procedures without increased major morbidity or mortality; however, the use of cardiopulmonary bypass has been associated with significantly increased morbidity and mortality in our patient population.
Collapse
Affiliation(s)
- F C Detterbeck
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill 27599-7065, USA
| | | | | |
Collapse
|
30
|
Abstract
Patients with cystic fibrosis (CF) are being considered in increasing numbers as candidates for lung transplantation, despite earlier concerns that their nutritional status and the infective nature of their lung disease would contribute to increased morbidity and mortality. We undertook a retrospective analysis of patients with CF referred for consideration of lung transplant to identify factors that helped to select suitable transplant candidates and to identify characteristics that predicted death while on the waiting list. Analysis of 95 referred patients with CF demonstrated a high rate of suitability (78%) by our criteria. The mean weight of listed patients with CF was 77% predicted, and the mean FEV1 was 20% predicted. Sixteen percent of listed patients with CF died awaiting transplant. The FEV1 of these patients was significantly lower than that of patients who survived to transplant. This study implies that patients with CF are being referred for transplant late in the course of their disease. Earlier referral may lead to an increase in the number of patients with CF undergoing successful lung transplantation.
Collapse
Affiliation(s)
- P Ciriaco
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill, USA
| | | | | | | | | | | |
Collapse
|
31
|
Hennington MH, Detterbeck FC. To be or not to be an organ donor? That is the question. N C Med J 1995; 56:170-1. [PMID: 7753219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- M H Hennington
- Division of Cardiothoracic Surgery, UNC School of Medicine, Chapel Hill 27599, USA
| | | |
Collapse
|
32
|
Egan TM, Thompson JT, Detterbeck FC, Lackner RP, Mill MR, Ogden WD, Aris RM, Paradowski LJ. Effect of size (mis)matching in clinical double-lung transplantation. Transplantation 1995; 59:707-13. [PMID: 7886797 DOI: 10.1097/00007890-199503150-00012] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Current United Network for Organ Sharing policy requires listing lung transplant recipients with an acceptable donor weight range, but lung size is a function of height, age, sex, and race. Frequently, lung transplant recipients are underweight, which results in a large discrepancy between donor and recipient weights. We reviewed our experience with size discrepancy between donors (D) and recipients (R) of 49 double-lung transplant (DLTX) procedures since July 1990. Pneumoreduction procedures were performed in 11 recipients of lungs judged to be too large at the time of DLTX (right middle lobectomy, 2; lingulectomy, 2; both, 6; right middle lobectomy and bilateral apical resections, 1). Predicted forced vital capacity (FVC) and total lung capacity (TLC) of donors and recipients were calculated. Donors were larger than recipients in general (D:R height = 1.02; D:R weight = 1.46), and, as a result, recipient-predicted lung volumes were smaller than donor-predicted lung volumes (D:R FVC = 1.1; D:R TLC = 1.1). Recipients undergoing pneumoreduction procedures had a significantly greater size discrepancy between donors and recipients; thus, both the ratio of D:R and the difference between D and R predicted FVC and TLC were significantly greater among recipients who underwent pneumoreduction, compared with nonreduced recipients. For recipients in the pneumoreduction group, predicted FVC and TLC were recalculated, with a proportionate amount subtracted based on the number of pulmonary segments removed. When the "corrected" FVC and TLC of the donors were compared with recipient-predicted FVC and TLC, there was no longer any significant difference between reduced and non-reduced groups, which implies that visual estimate of size mismatch at surgery is an accurate measure of size discrepancy. Post-DLTX spirometry showed identical improvement in FVC in patients who had pneumoreduction and those who did not, and survival at 6 months was identical in both groups. We conclude that pneumoreduction had no adverse effect on survival or post-DLTX spirometry, allowing safe use of larger donors in small recipients. Also, because lung size is more a function of height than weight, this study challenges the United Network for Organ Sharing practice of listing recipients with an acceptable donor weight range.
Collapse
Affiliation(s)
- T M Egan
- Department of Surgery, University of North Carolina School of Medicine, Chapel Hill 27599
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
A 3-month-old infant with failure to thrive was found on bronchoscopy to have tracheal obstruction thought to be secondary to innominate artery compression. Subsequent diagnostic evaluation with magnetic resonance imaging revealed superior and posterior extension of the thymus with resultant compression of the innominate artery and trachea within the narrow confines of the thoracic inlet. Resection of the aberrantly positioned and enlarged thymus and aortopexy resulted in relief of tracheal compression.
Collapse
Affiliation(s)
- M H Hennington
- Department of Surgery, University of North Carolina School of Medicine, Chapel Hill
| | | | | | | |
Collapse
|
34
|
Egan TM, Detterbeck FC, Mill MR, Paradowski LJ, Lackner RP, Ogden WD, Yankaskas JR, Westerman JH, Thompson JT, Weiner MA. Improved results of lung transplantation for patients with cystic fibrosis. J Thorac Cardiovasc Surg 1995; 109:224-34; discussion 234-5. [PMID: 7531796 DOI: 10.1016/s0022-5223(95)70383-7] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Patients with cystic fibrosis pose particular challenges for lung transplant surgeons. Earlier reports from North American centers suggested that patients with cystic fibrosis were at greater risk for heart-lung or isolated lung transplantation than other patients with end-stage pulmonary disease. During a 3 1/2 year period, 44 patients with end-stage lung disease resulting from cystic fibrosis underwent double lung transplantation at this institution. During the same interval, 18 patients with cystic fibrosis died while waiting for lung transplantation. The ages of the recipients ranged from 8 to 45 years, and mean forced expiratory volume in 1 second was 21% predicted. Seven patients had Pseudomonas cepacia bacteria before transplantation. Bilateral sequential implantation with omentopexy was used in all patients. There were no operative deaths, although two patients required urgent retransplantation because of graft failure. Cardiopulmonary bypass was necessary in six procedures in five patients and was associated with an increased blood transfusion requirement, longer postoperative ventilation, and longer hospital stay. Actuarial survival was 85% at 1 year and 67% at 2 years. Infection was the most common cause of death within 6 months of transplantation (Pseudomonas cepacia pneumonia was the cause of death in two patients), and bronchiolitis obliterans was the most common cause of death after 6 months. Actuarial freedom from development of clinically significant bronchiolitis obliterans was 59% at 2 years. Results of pulmonary function tests improved substantially in survivors, with forced expiratory volume in 1 second averaging 78% predicted 2 years after transplantation. Double lung transplantation can be accomplished with acceptable morbidity and mortality in patients with cystic fibrosis.
Collapse
Affiliation(s)
- T M Egan
- Division of Cardiothoracic Surgery (Department of Surgery), University of North Carolina at Chapel Hill
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994; 149:1601-7. [PMID: 7516251 DOI: 10.1164/ajrccm.149.6.7516251] [Citation(s) in RCA: 140] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
It has been suggested that the presence of airway pathogens prior to lung transplantation (LT) in patients with cystic fibrosis (CF) may place these patients at a higher risk for infectious complications after LT. There is particular concern regarding patients colonized with multiresistant Pseudomonas, including P. cepacia, and fungi, including Aspergillus. We report our experience with LT for patients with CF and compare the results with those of patients with LT for other indications. Between January 1990 and March 1993, we performed LT for 27 patients with CF and 32 without CF. Nearly all (89%) of the patients with CF were colonized with P. aeruginosa; many were cultured with P. cepacia (19%) and Aspergillus (63%). The non-CF group rarely had organisms identified pre-LT. No patients with CF underwent pre-LT sinus drainage or received pre-LT treatment for Aspergillus. All of the patients received perioperative antibiotics and a standard regimen of immunosuppression and prophylactic antibiotics. The incidence of infectious complications was the same in the two groups; however, there was an association between obliterative bronchiolitis and pulmonary infections. One of the patients with CF with P. cepacia died as a result of this organism. None of the patients with CF required treatment for Aspergillus post-transplant. We conclude that patients with CF, despite the presence of airway pathogens, are at no greater risk of infectious complications after LT than are other patients.
Collapse
Affiliation(s)
- P A Flume
- Department of Medicine, University of North Carolina at Chapel Hill
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
Kearns-Sayre syndrome is the triad of progressive external ophthalmoplegia, pigmentary retinopathy, and complete AV block. The etiology is unknown, but is thought to be due to a mitochondrial DNA deletion. Reported electrocardiographic abnormalities include first-degree AV block, fascicular blocks, and complete heart block, as well as non-specific S-T segment changes and T wave abnormalities, but has not included sinus node dysfunction. We report a case with episodes of sinus arrest in an asymptomatic patient with Kearns-Sayre syndrome resulting in pauses lasting up to 6 seconds.
Collapse
Affiliation(s)
- K S Ulicny
- Department of Surgery, University of North Carolina School of Medicine, Chapel Hill
| | | | | |
Collapse
|
37
|
Abstract
In our armamentarium of various thoracic incisions, we have incorporated a vertical skin incision with a muscle-sparing approach to gain access to the thorax. We find this incision gives excellent exposure, preserves function of the chest wall musculature, and leaves a cosmetically superior result.
Collapse
Affiliation(s)
- M H Hennington
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill
| | | | | |
Collapse
|
38
|
Flume PA, Egan TM, Westerman JH, Paradowski LJ, Yankaskas JR, Detterbeck FC, Mill MR. Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant 1994; 13:15-21; discussion 22-3. [PMID: 7513185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
As lung transplantation has become more successful, the selection criteria have broadened; however, some relative contraindications to lung transplantation are controversial. Some programs consider mechanical ventilation to be a major contraindication to lung transplantation because airway colonization with bacteria may lead to nosocomial infection and respiratory muscle deconditioning may necessitate prolonged postoperative ventilatory support. We report our experience of seven double lung transplant procedures on six patients requiring mechanical ventilation. Five patients with cystic fibrosis required preoperative mechanical ventilation for 7 to 19 days (mean, 10.7 days). One patient with acute lung injury required 115 days of preoperative mechanical ventilatory support. Only the latter patient required prolonged (27 days) postoperative mechanical ventilation because of respiratory muscle weakness; the others were extubated in 1 to 19 days (mean, 7.8 days). No early complications related to bacterial infection were seen. Two patients required temporary hemodialysis for transient kidney failure. Three patients had postoperative neurologic residua; one patient had a transient hemiparesis, and seizures developed in two patients. One patient died 3 months after transplantation from severe central nervous system complications with no evidence of pulmonary problems; and two patients died 17 months after transplantation, one of them receiving a second double lung transplant for obliterative bronchiolitis. Except for the patient who required prolonged preoperative ventilatory support, mechanical ventilation did not appear to play a role in the outcome of these patients. The posttransplantation hospital stay and hospital charges for patients requiring pretransplantation ventilatory support were not significantly different from those for other lung transplant recipients.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- P A Flume
- Department of Medicine, University of North Carolina School of Medicine, Chapel Hill
| | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
Esophago-arterial fistula is a rare but life-threatening complication of an aberrant subclavian artery aneurysm. We report the computed tomography appearance of such a fistula. The characteristic location, presence of rim calcification, and interspersed air and thrombus allowed for prompt preoperative diagnosis and surgery.
Collapse
Affiliation(s)
- D M Warshauer
- Department of Radiology, University of North Carolina, Chapel Hill 27599-7510
| | | | | |
Collapse
|
40
|
Abstract
An anomalous course of the left brachiocephalic vein beneath the aortic arch was identified in 7 patients undergoing surgical repair of congenital cardiac malformations. Six of these patients had the morphologic features of tetralogy of Fallot including severe obstruction to the right ventricular outflow tract and a right aortic arch. A review of the literature reveals this to be an uncommon anomaly. When it is present, however, it is frequently associated with a ventricular septal defect, obstruction of the right ventricular outflow, and aortic arch anomalies. This anomaly can be documented by echocardiography, at cardiac catheterization, or intraoperatively. The presence of a subaortic left brachiocephalic vein may have implications for the conduct of surgical procedures, especially in the setting of tetralogy of Fallot.
Collapse
Affiliation(s)
- M R Mill
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill
| | | | | | | |
Collapse
|
41
|
Abstract
Fungi cause serious, often fatal infections in immunocompromised hosts. Recipients of solid organ and bone marrow transplants are predisposed to invasive fungal infections with Candida species, Aspergillus species, and Cryptococcus neoformans. In contrast, infections with Blastomyces dermatitidis have rarely been diagnosed in transplant recipients. We describe a patient who received an orthotopic heart transplant and developed recurrent disseminated blastomycosis. Other reported cases of blastomycosis in transplant recipients are summarized. Clinical presentation, treatment options, and morbidity associated with infections with B. dermatitidis in transplant patients are reviewed.
Collapse
Affiliation(s)
- J S Serody
- Department of Medicine, University of North Carolina School of Medicine, Chapel Hill 27599-7030
| | | | | | | | | |
Collapse
|
42
|
Abstract
We present a method of pacemaker implantation in neonates using a subxyphoid epicardial lead and subrectus placement of the pulse generator. This method is simple and safe and carries minimal morbidity.
Collapse
Affiliation(s)
- K S Ulicny
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill 27599-7065
| | | | | | | |
Collapse
|
43
|
Abstract
A 26-year-old woman with end-stage lung disease due to eosinophilic granulomatosis had single right lung transplantation with an excellent function result that persists beyond 9 months of follow-up. Single lung transplantation offers excellent palliation to selected patients with end-stage lung disease.
Collapse
Affiliation(s)
- T M Egan
- Divisions of Cardiothoracic Surgery and Pulmonary Medicine, University of North Carolina School of Medicine, Chapel Hill
| | | | | | | | | | | |
Collapse
|
44
|
Egan TM, Westerman JH, Lambert CJ, Detterbeck FC, Thompson JT, Mill MR, Keagy BA, Paradowski LJ, Wilcox BR. Isolated lung transplantation for end-stage lung disease: a viable therapy. Ann Thorac Surg 1992; 53:590-5; discussion 595-6. [PMID: 1554266 DOI: 10.1016/0003-4975(92)90316-v] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Since January 1990, we have performed 29 isolated lung transplantations in 28 patients with end-stage lung disease (12 single, 16 bilateral). Recipient diagnoses were: cystic fibrosis (11), chronic obstructive pulmonary disease (6), pulmonary fibrosis (6), eosinophilic granulomatosis (1), postinfectious lung disease (1), adult respiratory distress syndrome (1), and primary pulmonary hypertension (2). There have been four deaths, two in patients with pulmonary fibrosis and two in patients with primary pulmonary hypertension. Four patients have undergone transplantation while on ventilatory support for respiratory failure (2 with cystic fibrosis, 1 having redo lung transplantation with cystic fibrosis, and 1 with adult respiratory distress syndrome); all of these have survived. Six patients required cardiopulmonary bypass, which was associated with increased transfusion requirement. All patients 2 months after discharge have returned to an active life-style, except for 2 patients who currently await retransplantation. Preoperative pulmonary rehabilitation has resulted in significant improvement in exercise performance in all patients. Immunosuppression consists of cyclosporine, azathioprine, and antilymphoblast globulin (University of Minnesota), withholding systemic steroids in the early postoperative period. We have employed bronchial omentopexy in all but four transplants; there has been one partial bronchial dehiscence, two instances of bronchomalacia requiring internal stenting, and one airway stenosis. Cytomegalovirus disease has been seen frequently (15 cases), but has responded well to treatment with ganciclovir. Other complication shave included one drug-related prolonged postoperative ventilation, thrombosis of a left lung after bilateral lung transplantation requiring retransplantation, five episodes of unilateral phrenic nerve palsy after bilateral lung transplantation (4 resolved), and the requirement of massive transfusion (greater than 10 units) in 5 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- T M Egan
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
Current preservation techniques for lung transplantation limit ischemic time to 6 hours. The purpose of this study was to evaluate the ability of dimethylthiourea, a low molecular weight free radical scavenger, to prolong this interval. An in vivo canine transplantation model was used to assess lung function. At harvest and after circulatory arrest, the donor lung was flushed with modified Euro-Collins solution (50 mL/kg). In a blinded fashion, dimethylthiourea (5 g) or saline solution was added to the flush solution at harvest and also infused (20 g over 2 hours) at reimplantation. Harvested lungs were stored for 12 hours at 4 degrees C. Allotransplantation was performed in recipient dogs ventilated with 40% O2. After 1 hour, the contralateral pulmonary artery was ligated, forcing the dog to be dependent on the transplanted lung. Twelve dogs were studied, with 6 randomly assigned to each treatment group in a blinded fashion. Measurements were recorded for 8 hours, keeping the inspired oxygen fraction constant at 0.40. All dimethylthiourea-treated dogs survived the observation period, whereas one third of the dogs that received saline solution died. Dimethylthiourea-treated dogs had significantly greater arterial oxygen tension and significantly less pulmonary vascular resistance compared with control animals. These results suggest that treatment of the lung with a free radical scavenger (dimethylthiourea) improves pulmonary function after reimplantation in a canine model after 12-hour hypothermic storage.
Collapse
Affiliation(s)
- C J Lambert
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill
| | | | | | | | | |
Collapse
|
46
|
Abstract
An in vivo canine model was used to assess the ability of an oxygen free radical scavenger to decrease reperfusion injury in lung transplantation. In 12 dogs, the left lungs were transplanted after they had been preserved for 24 hours at 4 degrees C after pulmonary artery flushing with modified Eurocollins solution. In 6 dogs, dimethylthiourea, a potent oxygen free radical scavenger, was added to the flush solution and was also given to the recipients just before reperfusion. In all animals, the contralateral pulmonary artery and bronchus were ligated and lung function was assessed for 12 hours or until death. Three dogs died prematurely in the control group, whereas only 1 dog died prematurely in the dimethylthiourea group. This resulted in a statistically significant difference in the average length of survival (p less than 0.05). Pulmonary artery and right atrial pressures were significantly lower in the dimethylthiourea group during the first 6 hours (p less than 0.05). Treatment with dimethylthiourea resulted in a significantly higher arterial oxygen tension at 4 hours, and intrapulmonary shunt tended to be lower. Thus, it would appear that dimethylthiourea has a protective effect on lungs preserved for 24 hours before transplantation in dogs.
Collapse
Affiliation(s)
- F C Detterbeck
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill
| | | | | | | |
Collapse
|